<DOC>
	<DOCNO>NCT01605344</DOCNO>
	<brief_summary>The purpose study evaluate effect atorvastatin pharmacokinetic profile irinotecan SN-38 . To evaluate safety atorvastatin combination FOLFIRI . To evaluate safety irinotecan combination atorvastatin .</brief_summary>
	<brief_title>Crossover Evaluation Effect Atorvastatin PK Irinotecan CRC Patients Receiving FOLFIRI</brief_title>
	<detailed_description>This single-center , prospective , randomize , crossover study address pharmacokinetic effect atorvastatin irinotecan metabolism patient receive first cycle FOLFIRI ( 5-fluorouracil + leucovorin + irinotecan ) . Each cycle FOLFIRI define 28 day , dose FOLFIRI administer day 1 day 15 . Patients recruit UNC Lineberger Cancer Center , refer primary oncologist treatment metastatic colorectal cancer ( mCRC ) . After obtain informed consent , patient randomize either ARM A ARM B . Blood sample collect day 1 15 FOLFIRI prior treatment irinotecan ( baseline ) , immediately follow end irinotecan infusion , 0.5 , 1 , 1.5 , 2 , 4 , 6 , 24 hour follow end irinotecan infusion . ARM A subject receive atorvastatin 20 mg orally daily give two week start Day -14 PERIOD ONE . ARM A receive statin PERIOD TWO . Patients receive FOLFIRI infusion day 1 day 15 . Blood sample collect baseline periodically 24 hour . ARM B subject receive atorvastatin PERIOD ONE . ARM B subject receive atorvastatin 20 mg orally daily two week PERIOD TWO ( start Day 2 ) . Patients receive FOLFIRI infusion day 1 day 15 . Blood sample collect baseline periodically 24 hour . DNA extraction genetic analysis UGT1A1 polymorphism perform collaboration Dr. Federico Innocenti patient homozygous UGT1A1*28 allele exclude due altered irinotecan metabolism . Patients follow Day 1 Cycle 2 FOLFIRI . Patients remove study unacceptable adverse event follow resolution stabilization event ( ) .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>1 . Age ≥18 year age ( upper age limit ) 2 . Histological cytological documentation adenocarcinoma colon rectum , patient schedule begin FOLFIRI treatment metastatic disease 3 . Patients take statins time enrollment permit . Patients take statin ( one prohibit drug , see section 4.2.27 section 12.1 ) must agree 2 week washout prior treatment atorvastatin ( see Schema ) section 5.2 4 . Life expectancy least 3 month 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤1 6 . Adequate bone marrow , renal , hepatic function , evidence follow within 7 day treatment initiation atorvastatin ( nothing , enrol Arm B ) : absolute neutrophil count ( ANC ) ≥1,500/mm3 platelet ≥100,000/mm3 hemoglobin ≥9.0 g/dL serum creatinine ≤1.5 x upper limit normal ( ULN ) AST ALT ≤ 3 x ULN Total bilirubin ≤ 1.5 x ULN Alkaline phosphatase ≤2.5 x ULN Amylase lipase ≤1.5 x ULN INR/PTT ≤1.5 x ULN CPK ≤ ULN 7 . Women childbearing potential male subject must agree use adequate contraception duration study participation . Adequate contraception define medically recommend method ( combination method ) per standard care . 8 . Medical oncologist agrees two week window appropriate/safe prior start FOLFIRI trial candidate . 9 . The subject capable understanding comply parameter outline protocol 10 . Signed , IRBapproved write informed consent 1 . Any prior allergy statin therapy adverse event preclude use , include limited myopathy , rhabdomyolysis , etc . Patients change atorvastatin another statin safety efficacy reason also exclude . 2 . Prior treatment FOLFIRI single agent irinotecan prohibit within six week enrollment . All prior toxicity previous irinotecan administration must resolve prior enrollment . No 2 prior therapeutic regimen metastatic disease allow . 3 . Patients allow receive bevacizumab EGFR inhibitor ( cetuximab panitumumab ) duration study ( 1 cycle ) . 4 . Patients baseline LDL ≤ 100 mg/dL currently treat statin 5 . Patients homozygous UGT1A1*28 allele , patient Asian descent homozygous heterozygous UGT1A1*6 allele exclude due altered irinotecan metabolism 6 . Pregnant breastfeeding patient . Women childbearing potential must pregnancy test perform maximum 7 day start atorvastatin FOLFIRI treatment , negative result must document start treatment atorvastatin FOLFIRI ( whichever receive first patient ) . 7 . Patients treat hematopoietic colonystimulating growth factor ( e.g. , GCSF , GMCSF ) ≤2 week prior start study drug . Erythropoietin darbepoetin therapy , initiate ≥2 week prior enrollment , may continue . 8 . History Gilbert 's syndrome 9 . Pernicious anemia anemia due Vitamin B12 deficiency ( due potential masking deficiency leucovorin ) 10 . Known Dihydropyrimidine dehydrogenase ( DPD ) deficiency 11 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day start Day 1 treatment FOLFIRI 12 . Any patient history stroke TIA within 6 month prior study enrollment 13 . Active cardiac disease include follow : Congestive heart failure ( New York Heart Association [ NYHA ] ) ≥Class 2 ( see Appendix C ) Unstable angina ( angina symptom rest ) , newonset angina ( begin within last 3 month ) . Myocardial infarction le 6 month start Day 1 FOLFIRI Cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) 14 . Ongoing infection &gt; Grade 2 accord NCI Common Terminology Criteria Adverse Events version 4.0 ( CTCAE v. 4.0 ) 15 . Known history human immunodeficiency virus ( HIV ) infection 16 . Presence acute chronic liver disease , renal disease pancreatitis 17 . Known history chronic hepatitis B C 18 . Symptomatic metastatic brain meningeal tumor unless patient &gt; 6 month definitive therapy , negative imaging study within 4 week FOLFIRI initiation , clinically stable respect tumor time study entry . Also , patient must undergo acute steroid therapy taper ( chronic steroid therapy acceptable provide dose s4.2.2table one month prior D1 treatment study ) 19 . History organ allograft 20 . Nonhealing wound , ulcer , bone fracture 21 . Known hypersensitivity study drug , study drug class , excipients formulation 22 . Inability swallow oral medication 23 . Evidence history bleed diathesis . Any hemorrhage bleeding event &gt; Grade 4 within 4 week start FOLFIRI 24 . Patients diarrhea CTCAE v4 grade ≥2 25 . Any malabsorption condition 26 . Unresolved toxicity high CTCAE v. 4.0 Grade 1 attribute prior therapy/procedure exclude alopecia oxaliplatininduced neurotoxicity ( must ≤Grade 2 ) 27 . Patients unable unwilling discontinue ( substitute necessary ) use prohibit drug , juice herbal supplement least 2 week prior atorvastatin initiation ( see Appendix A list prohibit drug , juice herbal supplement ) 28 . Substance abuse , medical , psychological , social condition may interfere patient 's participation study evaluation study result 29 . Unwilling provide consent genetic study whole blood plasma specimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Advanced colon cancer</keyword>
	<keyword>Advanced rectal cancer</keyword>
	<keyword>Metastatic colon cancer</keyword>
	<keyword>Metastatic rectal cancer</keyword>
	<keyword>Lipitor</keyword>
	<keyword>Atorvastatin</keyword>
	<keyword>FOLFIRI</keyword>
</DOC>